Shaw · Frontiers in physiology 2022 · Randomized controlled animal experiment · n=?

Examining Neurosteroid-Analogue Therapy in the Preterm Neonate For Promoting Hippocampal Neurodevelopment.

Level 5 - mechanism / opinion, no new human data

Bench or animal research

PubMed 35514343 · doi:10.3389/fphys.2022.871265 · record verified 2026-08-26

What was done

Preterm guinea pig pups (delivered at gestational day 62) were randomized to receive no treatment or daily ganaxolone at 0.5 mg/kg (low dose), 1.0 mg/kg (mid dose), or 2.5 mg/kg (high dose) until term-equivalence age (day 69), alongside spontaneously delivered term controls. Investigators assessed physical parameters (weight gain, ponderal index, supplemental feeding, and a composite wellbeing score). At term equivalence, hippocampal tissue was analyzed via immunohistochemistry and RT-PCR for markers of oligodendrocyte lineage (CSPG4, MBP), neuronal growth (INA, VEGFA), and GABAergic/glutamatergic signaling (SLC32A1, SLC1A2, GRIN1, GRIN2C, DLG4).

What was found

The abstract provides no exact numerical values, effect sizes, or p-values. High-dose ganaxolone (2.5 mg/kg) significantly worsened all recorded physical parameters and wellbeing scores over multiple postnatal days compared with untreated preterm controls. Low and mid doses showed mild effects on early weight gain, supplemental feeding, and wellbeing. Preterm birth induced deficits in hippocampal oligodendrocyte, neuronal growth, and neurotransmitter receptor markers, but ganaxolone treatment at any dose failed to alter or rescue these deficits at term equivalence.

Why it matters

This study demonstrates dose-dependent adverse systemic effects of ganaxolone in a preterm model and shows that short-term administration does not normalize early hippocampal molecular deficits by term equivalence.

Limits

Animal model findings cannot be directly translated to human preterm infants. The abstract omits sample sizes and exact numerical data. Outcomes were evaluated only at term equivalence without assessing long-term functional or behavioral recovery.

Cited by